Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ALLO
ALLOGENE THERAPEUTICS, INC.
NASDAQ
$1.97
▼ DOWN 0.51% (-0.01)

KEY STATISTICS

Market Cap$678.23 M
52w High$4.46
52w Low$1.04
Dividend Yield—
Frequency—
P/E-2.94
Volume4.43M
Shares Out.345.15M

COMPANY

LEADERSHIP

Zachary Roberts
CHIEF EXECUTIVE
Zachary Roberts

COMPENSATION 2026

Salary$724,000
Stock Awards$1,071,218
Incentive Plan Pay$400,010
All Other Comp.$14,217
Total$6,136,093

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 11, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
151

PRICE TARGET

Target High$9.00
Target Low$3.85
Target Median$6.42
Target Consensus$6.43

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$2.50K
NOV
5
THU

PRICE

$1.97 ▼ DOWN 0.51% (−$0.01)
$1.96$1.98$1.99$2.019:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM1.97

About Allogene Therapeutics, Inc.

https://www.allogene.com ↗

Allogene Therapeutics develops and commercializes genetically engineered allogeneic CAR T cell therapies for cancer, with multiple candidates in clinical trials targeting various hematologic and solid tumors.

INDUSTRY

Biotechnology

A PRODUCT ALLOGENE THERAPEUTICS, INC. IS KNOWN FOR

cemacabtagene ansegedleucel (cema-cel)
cemacabtagene ansegedleucel (cema-cel)

Cema-cel is an allogeneic, off-the-shelf CAR T-cell therapy in Phase 2 for large B-cell lymphoma, aiming to provide a rapid, frontline treatment option through its innovative ALPHA3 trial.

COMPETITORS

COMPETITOR
CLLS COMPARE
CRBU COMPARE
CRSP COMPARE
FATE COMPARE
NKTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Reportable Segment— — — $4.64M
License$4.6M $0 ▼$4.6M ▲—

ETFS HOLDING THIS STOCK

ETFS HOLDING
99
LISTED HERE
20
RANKED BY POSITION SIZE
XBI
0.22% · 12.9M
VTI
0.00% · 8.7M
XSU.TO
0.02% · 6.8M
FESM
0.06% · 2.0M
SCHA
0.01% · 1.3M
DFAS
0.01% · 1.0M
PRFZ
0.04% · 618.1K
SBIO
0.38% · 475.6K
LABU
0.15% · 432.0K
XRSU.L
0.02% · 236.0K
AVSC
0.01% · 168.7K
BBC
0.64% · 165.1K
WBIO.L
0.64% · 134.5K
RSSL
0.02% · 126.0K
CN
CNCR
3.29% · 60.6K
MEDX
0.17% · 15.2K
BIB
0.02% · 12.3K
SZNE
0.04% · 5.6K
RESM
0.02% · 510
CHEP
0.00% · -69

INSTITUTIONAL OWNERSHIP

SHARES OWNED
60.61%
HOLDERS
289
TOP 12 OF 289 · RANKED BY POSITION SIZE
Blackrock, Inc.
30.1M sh · $62.71M
Frazier Life Sciences Management, L.P.
22.4M sh · $46.69M
Pfizer Inc
22.0M sh · $46.93M
State Street Corp
19.0M sh · $39.57M
Tpg Gp A, LLC
18.7M sh · $38.93M
Tpg Group Holdings (Sbs) Advisors, Inc.
18.7M sh · $481.01M
Blackrock Inc.
16.4M sh · $38.32M
Citadel Advisors LLC
14.0M sh · $17.32M
Sio Capital Management, LLC
13.3M sh · $27.71M
Primecap Management Co/Ca/
13.1M sh · $27.3M
Fmr LLC
12.0M sh · $24.98M
Vanguard Group Inc
9.3M sh · $12.67M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: SVP, GENERAL COUNSEL
Douglas Earl Martin
Sale · 29.7K shares
2026-08-21
★
OFFICER: PRESIDENT AND CEO
Roberts Zachary
Purchase · 476.2K shares
2026-07-01
★
OFFICER: PRESIDENT AND CEO
Roberts Zachary
Purchase · 134.5K shares
2026-07-01
★
DIRECTOR
Kazam Joshua A
Purchase · 47.7K shares
2026-06-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
MARKET PERFORM 2
MARKET OUTPERFORM 1
NEUTRAL 1
OUTPERFORM 1
OVERWEIGHT 1
9 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM HC Wainwright & Co. BUY JP Morgan NEUTRAL Jefferies BUY Argus Research MARKET PERFORM Baird OUTPERFORM Bernstein MARKET PERFORM Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
ACHV$8.49COMPARE
CABA$3.46COMPARE
KYTX$8.33COMPARE
EDIT$3.16COMPARE
AVIR$5.87COMPARE
VNDA$5.41COMPARE
VYGR$3.49COMPARE
CRBU$1.57COMPARE